CorMedix Inc.

    Jurisdiction
    United States
    LEI
    5299006YIA3L0MBW8358
    ISIN
    US21900C3088 (CRMD)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    47 / 100
    Worse than peer group:
    49 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €103.62M
    Gross margin
    95.6%
    EBIT
    €42.07M
    EBIT margin
    40.6%
    Net income
    €43.64M
    Net margin
    42.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €338.49M +226.7% €170.58M +290.9%
    €360.23M +6.4% €194.55M +14.1%
    €400.34M +11.1% €205.20M +5.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 9, 2024 (Q1 2024)

    Add to watchlist

    Notifications